Bio-Techne (TECH) FY Conference June 03, 2025 03:40 PM ET Speaker0 Thanks everyone for hanging with us towards the end of the day here. And thanks for joining us for the Biotechnology Management Presentation. My name is Matt Larue. Very happy to have CEO Kim Kelderman here and Dave Claire from IR is here as well. So thanks to them for joining us. I have two logistical comments. One, the breakout is in Maher on the Second Floor. And then second, for a list of our research disclosures and conflicts of interes ...

Company Performance - Ekso Bionics reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.11, and an improvement from a loss of $0.20 per share a year ago, indicating a negative earnings surprise of -9.09% [1] - The company posted revenues of $3.38 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 28.95%, and down from $3.76 million in the same quarter last year [2] - Over the last four quarters, Ekso Bionics has not surpassed consensus EPS or revenue estimates [2] Stock Outlook - Ekso Bionics shares have declined approximately 20.8% since the beginning of the year, compared to a decline of -3.3% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $6.32 million, and for the current fiscal year, it is -$0.25 on revenues of $23.99 million [7] - The estimate revisions trend for Ekso Bionics is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Ekso Bionics belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Wall Street analysts forecast that Hologic (HOLX) will report quarterly earnings of $1.02 per share in its upcoming release, pointing to a year-over-year decline of 1%. It is anticipated that revenues will amount to $1 billion, exhibiting a decline of 1.6% compared to the year-ago quarter. Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections duri ...